DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
22 mars 2022 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Participate in Upcoming Conferences
02 mars 2022 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that members of its management team will participate in the...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Participate in Upcoming Conferences
07 févr. 2022 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
04 janv. 2022 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
07 déc. 2021 16h15 HE | Daré Bioscience, Inc.
Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisThis marks the first FDA-approved product in Daré’s portfolio of potential first...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
10 nov. 2021 08h00 HE | Daré Bioscience, Inc.
Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 ...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
09 nov. 2021 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021
03 nov. 2021 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021
06 oct. 2021 08h51 HE | Daré Bioscience, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
27 sept. 2021 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver...